Story thread · 2 reports / 2 sources
BioMarin does another small deal to get early-stage bone disease asset
endpts.com · 3h · first report
How the coverage leans
Across 2 sources · syndicated copies counted once
A week after ending development of a rare disease drug from a $270 million acquisition, BioMarin is back at the dealmaking table for a very similar number. The California biopharma
The coverage
- BioMarin acquires experimental drug for rare bone disorder in $275M deal
biopharmadive.com · 2h
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.